Status: Recruiting
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from a traumatic cervical or thoracic injuries.
Participants needed: 10
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Lineage Cell Therapeutics, Inc.Updated: Feb 12, 2026Locations: 2
Eligibility criteria
Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) or sensory incomp... [+8]
SCI due to penetrating trauma [+10]